耐多药艾滋病病毒感染者中的癌症。

IF 3.4 2区医学 Q3 IMMUNOLOGY

AIDS Pub Date : 2024-10-01 Epub Date: 2024-08-29 DOI:10.1097/QAD.0000000000003952

Tommaso Clemente, Domenico Pontillo, Vincenzo Malagnino, Leonardo Calza, Antonio Di Biagio, Giovanni Cenderello, Riccardo Lolatto, Elio Manzillo, Maria Cristina Moioli, Giuseppe Vittorio De Socio, Antonella Castagna, Vincenzo Spagnuolo

{"title":"耐多药艾滋病病毒感染者中的癌症。","authors":"Tommaso Clemente, Domenico Pontillo, Vincenzo Malagnino, Leonardo Calza, Antonio Di Biagio, Giovanni Cenderello, Riccardo Lolatto, Elio Manzillo, Maria Cristina Moioli, Giuseppe Vittorio De Socio, Antonella Castagna, Vincenzo Spagnuolo","doi":"10.1097/QAD.0000000000003952","DOIUrl":null,"url":null,"abstract":"Retrospective, cohort analysis including people with HIV and 4-class drug resistance (4DR). The 8-year probability of malignancy after first evidence of 4DR was 12%, with an incidence of 1.6/100 person years of follow-up. Cancer risk tended to increase with higher precancer viremia copy-years adjusted for time [per 1 - log10 copies/ml higher: adjusted hazard ratio (aHR) = 1.35; 95% confidence interval (95% CI) = 0.98-1.85] and male sex-assigned-at-birth (aHR = 2.50; 95% CI = 0.86-7.27). Efforts to achieve long-term undetectability, risk factor control, prevention, and more aggressive cancer screening are needed in this fragile population.","PeriodicalId":7502,"journal":{"name":"AIDS","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cancer in people with multidrug-resistant HIV.\",\"authors\":\"Tommaso Clemente, Domenico Pontillo, Vincenzo Malagnino, Leonardo Calza, Antonio Di Biagio, Giovanni Cenderello, Riccardo Lolatto, Elio Manzillo, Maria Cristina Moioli, Giuseppe Vittorio De Socio, Antonella Castagna, Vincenzo Spagnuolo\",\"doi\":\"10.1097/QAD.0000000000003952\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Retrospective, cohort analysis including people with HIV and 4-class drug resistance (4DR). The 8-year probability of malignancy after first evidence of 4DR was 12%, with an incidence of 1.6/100 person years of follow-up. Cancer risk tended to increase with higher precancer viremia copy-years adjusted for time [per 1 - log10 copies/ml higher: adjusted hazard ratio (aHR) = 1.35; 95% confidence interval (95% CI) = 0.98-1.85] and male sex-assigned-at-birth (aHR = 2.50; 95% CI = 0.86-7.27). Efforts to achieve long-term undetectability, risk factor control, prevention, and more aggressive cancer screening are needed in this fragile population.\",\"PeriodicalId\":7502,\"journal\":{\"name\":\"AIDS\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/QAD.0000000000003952\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000003952","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

回顾性队列分析，包括艾滋病病毒感染者和4类耐药性（4DR）患者。首次发现 4DR 后 8 年的恶性肿瘤概率为 12%，随访期间的发病率为 1.6/100 人年。经时间调整后，癌症风险往往随着癌前病毒拷贝数-年数的增加而增加[每增加1-log10拷贝数/毫升：调整后危险比（aHR）=1.35；95%置信区间（95% CI）=0.98-1.85]以及出生时性别为男性（aHR=2.50；95% CI=0.86-7.27）。在这一脆弱人群中，需要努力实现长期检测不到、风险因素控制、预防和更积极的癌症筛查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cancer in people with multidrug-resistant HIV.

Retrospective, cohort analysis including people with HIV and 4-class drug resistance (4DR). The 8-year probability of malignancy after first evidence of 4DR was 12%, with an incidence of 1.6/100 person years of follow-up. Cancer risk tended to increase with higher precancer viremia copy-years adjusted for time [per 1 - log10 copies/ml higher: adjusted hazard ratio (aHR) = 1.35; 95% confidence interval (95% CI) = 0.98-1.85] and male sex-assigned-at-birth (aHR = 2.50; 95% CI = 0.86-7.27). Efforts to achieve long-term undetectability, risk factor control, prevention, and more aggressive cancer screening are needed in this fragile population.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

AIDS 医学-病毒学

CiteScore

5.90

自引率

5.30%

发文量

478

审稿时长

3 months

期刊介绍： Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.